Market Overview

Graminex® LLC successfully challenges Serelys' patents for use of pollen extracts in treating women's PMS and menopausal symptoms

Share:

Graminex® LLC is pleased to announce the US Patent Office has
rejected Serelys' patents for use of its pollen extracts in treating
women's PMS and menopausal symptoms.

In parallel reexamination proceedings against US Patents 6,569,471 and
6,669,967, the US Patent Office recently rejected all claims of both
patents. Based on overwhelming evidence submitted, the Office found the
claimed solvent-extracted GC FEM and PI 82 pollen extracts, for use in
treating PMS and menopausal symptoms in women, to be unpatentable. The
Final Rejections are available for download at USPTO Public PAIR (https://portal.uspto.gov/pair/PublicPair)
under reexamination serial numbers 90/014,026 and 90/014,027, where a
full public record of the evidence and detailed explanation for the loss
of patent coverage can be found.

Graminex® LLC is the only producer of Non-Solvent Rye Flower
Pollen Extract™. Only Graminex® Flower Pollen Extract™ is
solvent free. Keep It Clean™, our guarantee against solvent residues.

About Graminex® LLC

Graminex® LLC is the leading producer of natural and
solvent-free Graminex® Flower Pollen Extract™. Graminex®
directly owns and manages more than 8,500 acres of farmland in Northwest
Ohio. Graminex's® active raw ingredients are grown and
processed for use in the dietary supplement, pharmaceutical, food and
skin care industries. Graminex® markets clinically supported
Flower Pollen Extracts™, focusing on prostate care, urinary care,
menopausal support, and skin care. Partnered with its distributors,
retailers and manufacturers, Graminex® products are made in
the USA and sold in more than 44 countries on six continents.

For further information please contact Graminex® LLC Public
Relations, Colleen E. May at (419) 278-1023 or by e-mail at info@graminex.com.
You may also visit www.graminex.com.

View Comments and Join the Discussion!